---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Expected outcomes of therapy"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Expected outcomes of therapy. Topics: Guideline definition of disease-modifying therapy, Guideline treatment goals and follow-up, Natural history progression benchmark and company-presented progression with long-term adrabetadex, Investigator statement: lost neurological function is not regained, and 2 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Summary

- Treatment goals: disease-modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and extending lifespan beyond that predicted by natural history data. Treatment goals are established at diagnosis and reviewed regularly, aiming to improve or maintain physical and psychosocial wellbeing.
- Survival in the label analysis: the FDA examined the survival of 36 participants treated with Lembaz across three clinical studies and an expanded access program against a matched external control group. Deaths occurred in 12 (33.3%) LEMBAZ-treated participants and 24 (66.9%) controls; the hazard ratio for death was 0.45 (95% CI 0.21, 0.95), a 55% reduction in the risk of death, and median survival was 8.5 years with treatment and 4.9 years in controls. Longer overall survival was observed independent of baseline miglustat use.
- Survival in a separate company analysis: deaths occurred in 17 (23.6%) adrabetadex-treated participants and 44 (61.2%) external controls, with a hazard ratio of 0.289 (95% CI 0.141, 0.593; P < 0.0001), reported by the company as a 71% reduction in the risk of mortality; the 5-year survival rate was 84% with adrabetadex and 42% in external controls.
- Disease progression: in a company analysis of 79 treated participants, the annual rate of progression on the rescored 4-domain NPCCSS fell from 1.34 units/year before treatment to 0.76 units per year after treatment, a 43% reduction (P=0.0055). An observational cohort receiving routine clinical care progressed by 1.5 units/year on the 5-domain NPCCSS. The company approval announcement states: “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”. Among five individuals treated with intrathecal HPBCD for 4 to 11 years, some disease progression continued.
- Expected harm: treatment with LEMBAZ has resulted in permanent hearing impairment; 37% (22/59) of patients in Trial 3 and an expanded access program experienced hearing impairment.

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Porter et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Porter_2026_NORD_Poster-Encore_Survival-NPCCSS-Biomarkers_QR_07OCT26_FINAL.pdf); [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/); [Berry-Kravis et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/Beren-WorldSymp-2026-Survival-NPCCSS-LB-Poster-01.30.2026_FINAL.pdf); [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf); [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/); [Matsuo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38448301/)

<a id="topic-2.2.2.7-2"></a>

### Guideline definition of disease-modifying therapy

> “For the purpose of this paper, disease‐modifying therapy in NPC is defined as an intervention that favorably alters the rate of disease progression, improving quality of life and ultimately extending lifespan beyond that predicted by available natural history data.”
> “To understand the effects of disease‐modifying therapy in NPC, information about the natural history of disease progression is required.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.7-3"></a>

### Guideline treatment goals and follow-up

> “Statement #19: NPC is a progressive condition, and patients require regular follow‐up to monitor disease severity, treatment response, and recurrence.”
> “Treatment goals should be established at diagnosis and reviewed regularly, aimed at improving or maintaining the physical and psychosocial wellbeing of individuals with NPC and their families.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.7-4"></a>

### Natural history progression benchmark and company-presented progression with long-term adrabetadex

> “In an observational cohort of individuals with NPC receiving routine clinical care, an annualized progression rate of 1.5 units/year was observed on the 5-domain NPC Clinical Severity Scale (NPCCSS).”
> “Both prompt and delayed adrabetadex treatment were associated with slower disease progression relative to published natural history data.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.7-5"></a>

### Investigator statement: lost neurological function is not regained

> “Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical”

Source: [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/)

<a id="topic-2.2.2.7-6"></a>

### Stabilization as a clinically meaningful outcome in rapidly progressive infantile-onset disease

> “In rapidly progressive infantile - onset NPC, stabilization and improvement are considered clinically - meaningful outcomes indicative of clinical improvement”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

<a id="topic-2.2.2.7-7"></a>

### Long-term intrathecal HPβCD: stabilization without complete arrest of progression

> “Furthermore, long-term treatment with IT-HPBCD may suppress neurological deterioration in patients with NPC; however, patients still experience some disease progression.”

Source: [Matsuo et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38448301/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
